Resources

11 Resources for

mike huckman and seeking alpha

Subscribe to this listing via:
RSS
Email

BNET Resources

Novo Nordisk: Approval of New Diabetes Drug Is Further Postponed: Mike Huckman submits: Novo Nordisk NVO, a company that has a vested interest in the diabetes market, is out with a new report pegging the cost of treating the disease at nearly a quarter-trillion dollars. According to the "National Changing Diabetes Program" which is sponsored by NVO, the...; Tags: Seeking Alpha, Mike Huckman, Outsourcing, It Operations, Business Operations, Outsourcing & Subcontracting, NUVO Network Management Inc., Biotech, Healthcare; External links 2008-11-18
Will Carl Icahn Come to Amylin's Rescue?: Mike Huckman submits: Wall Street has essentially thrown in the towel lately on Amylin Pharmaceuticals AMLN. The shares have plummeted from nearly $30 just three months ago to around $7 yesterday. But billionaire activist investor Carl Icahn apparently sees the stock as being on sale. At the end...; Tags: Carl Icahn, Seeking Alpha, Mike Huckman, Biotechnology, Amylin Pharmaceuticals Inc., Eli Lilly & Co., Biotech, Healthcare; External links 2008-11-17
Merck Rolls the Dice on New Januvia Study: Mike Huckman submits: The drug company that got into so much trouble when it uncovered and/or disclosed a cardiovascular side-effect of a popular painkiller Vioxx is launching a huge study to see if an up-and-coming diabetes drug is also bad for the heart. In a research note to clients...; Tags: Merck & Co. Inc., Seeking Alpha, Mike Huckman, Government, Healthcare, Web Site Development, Vertical Industries, Internet, Enterprise Software, Software; External links 2008-11-15
Charles River Labs: Caught in the Credit Crisis Crossfire: Mike Huckman submits: The so-called contract research organizations (CROs, for short) have been thought to be in the sweet spot of the current biopharma industry cost-cutting trend. More and more drug companies have been farming out an increasing amount of their research to firms like Charles River Labs CRL...; Tags: Seeking Alpha, Mike Huckman, Recruitment & Selection, Strategy, Human Resources, Workforce Management, Management, Charles River Laboratories International Inc., Biotech; External links 2008-11-06
Genzyme and Osiris Get Together on Stem Cells: Mike Huckman submits: In a bit of an election-day irony, a pretty significant stem cell deal is grabbing headlines in the biopharma sector. While it definitely took a back seat to the economy this election cycle, stem cell research has long been a hot-button political issue. John McCain supports...; Tags: Genzyme Corp., Stem-cell, Seeking Alpha, Mike Huckman, Barack Obama, Osiris Therapeutics Inc., Biotech; External links 2008-11-05

Merck Goes Back to School to Push HPV Vaccination: Mike Huckman submits: As a reporter, you never know when or where you might stumble on a story—or at least a blog entry. There I was Wednesday guest lecturing for an old friend's TV-news production class at my alma mater. So, while at the USC Annenberg School of Communications,...; Tags: Merck & Co. Inc., Seeking Alpha, Mike Huckman, Spyware, Spyware, Adware & Malware, Blogging, Viruses And Worms, Security, Internet, Healthcare; External links 2008-10-31
Will Merck's Job Cuts Help the Company?: Mike Huckman submits: You gotta feel sorry for the folks at Merck MRK. Immediately after the drugmaker finishes a program to get rid of more than 10,000 employees, the company drops the axe again. This time 7,200 people (12 percent of its workforce) will be let go by the...; Tags: Job, Merck & Co. Inc., Seeking Alpha, Mike Huckman, Workforce Management, Recruitment & Selection, Payroll Solutions, Human Resources, Healthcare; External links 2008-10-22
Roche: Why No News About Genentech from Earnings Call?: Mike Huckman submits: Genentech DNA investors who were hoping Roche (RHHBY.PK) would shed a little more light on the status of its proposed acquisition of the biotech giant might have hung up from the Swiss drugmaker's conference call a little disappointed. But apparently Roche, which trades on the Swiss...; Tags: Roche Holding AG, Genentech Inc., Earnings, Seeking Alpha, Mike Huckman, Biotechnology, Mergers & Acquisitions, Financial Accounting, Corporate Law, Investment, Finance, Business Operations, Biotech, Healthcare; External links 2008-10-22
How Will FDA Ruling Affect Eli Lilly's Effient?: Mike Huckman submits: I don't think Eli Lilly LLY will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration. Given the unpredictable nature of the agency and its...; Tags: Eli Lilly & Co., FDA, Seeking Alpha, Mike Huckman, Federal Government, Government, Healthcare; External links 2008-10-19
Dendreon Gets Another Analyst Thumbs-Down: Mike Huckman submits: I know I blogged as recently as last week that I thought there wouldn't be much reason to write about Dendreon DNDN for awhile, but I couldn't help myself when I got an email Wednesday night from Merriman Curhan Ford, which is launching coverage of DNDN...; Tags: Analyst, Seeking Alpha, Dendreon, Mike Huckman, E-mail, Investment, Online Communications, Finance, Dendreon Corp., Biotech; External links 2008-10-17
Genentech on Roche's Plans: Our Lips Are Sealed: Mike Huckman submits: On the Genentech DNA third quarter earnings conference call, analysts, investors and reporters were hoping to get some color on the status of the Roche (RHHBY.PK) play for the rest of DNA it doesn't already own. But from the outset CEO Art Levinson warned, "Don't even...; Tags: Roche Holding AG, DNA, Genentech Inc., Seeking Alpha, Mike Huckman, Biotechnology, Biotech; External links 2008-10-16